Previous 10 | Next 10 |
2023-05-11 16:04:20 ET Harrow Health press release ( NASDAQ: HROW ): Q1 Non-GAAP EPS of -$0.03. Revenue of $26.1M (+18.0% Y/Y) beats by $1.11M . For further details see: Harrow Health Non-GAAP EPS of -$0.03, revenue of $26.1M beats by $1.11M
First Quarter 2023 and Recent Selected Highlights: Record revenues of $26.1 million, up 18% over $22.1 million for the prior-year quarter and 28% over sequential quarter revenues of $20.3 million. Completed transfer of New Drug Applications (NDAs) for ILEVRO®, NEVANAC®, and MA...
Harrow Health, Inc. (NASDAQ: HROW) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.51% on the day to $27.44. Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical co...
Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the launch of FDA-approved IHEEZO ™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting being held May 5‑8, 2023, in San Diego, California. The Harrow commerc...
Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) for ILEVRO® (nepafenac ophthalmic suspension) 0.3%, NEVANAC® (nepafenac ophthalmic suspension) 0.1%, and MAXIDEX® (dexa...
Harrow Health, Inc. (NASDAQ: HROW) is the focus of IBN's latest stock spotlight. The company's shares have moved 2.73% on the day to $25.92. Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical co...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2023, on Thursday, May 11, 2023, after the market close. The Company will also post its first quarter Letter to Stockholders to th...
Harrow Health, Inc. (NASDAQ: HROW) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.72% on the day to $24.21. Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical co...
2023-04-04 08:47:51 ET Summary Harrow Health began commercial operations in 2014 with no products or customers, and today is the largest U.S. ophthalmic focused pharmacy. Harrow entered an opaque market filled with middle men and dissatisfied ophthalmologists. Harrow understands t...
B. Riley Leads Financing to Support Harrow Health Acquisition PR Newswire LOS ANGELES , March 28, 2023 /PRNewswire/ -- B. Riley Financial, Inc. (NASDAQ: RILY) ("B. Riley"), a diversified financial services platform, today announced that certain of its affiliates ...
News, Short Squeeze, Breakout and More Instantly...
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 8, 2024 Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Wednesday, August...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...